SEC Company Response from CervoMed Inc. (CRVO) (CIK 0001053691) (CRVO) — Oct 30, 2019
CervoMed Inc. (CRVO) (CIK 0001053691)
Date: Oct. 30, 2019 · CIK: 0001053691 · Accession: 0001437749-19-020944
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-234234
Letter
RE:
dffn20191030_corresp.htm
October 30, 2019
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, NE
Washington, DC 20549
Diffusion Pharmaceuticals Inc. Withdrawal of Request for Acceleration of
Registration Statement on Form S-1 (File No. 333-234234)
Ladies and Gentlemen:
Diffusion Pharmaceuticals Inc. (the “Registrant”) hereby withdraws its request, dated October 28, 2019, that the Registration Statement on Form S-1 (File No. 333-234234) (the “Registration Statement”) become effective on Wednesday, October 30, 2019, at 5:15 p.m., or as soon as practicable thereafter. The Registrant is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date.
If you have any questions regarding the foregoing, please contact our counsel, David Rosenthal of Dechert LLP at (212) 698-3616, or Curtis Weber of Dechert LLP at (212) 649-8705.
Very truly yours,
DIFFUSION PHARMACEUTICALS INC.
Show Raw Text
CORRESP 1 filename1.htm dffn20191030_corresp.htm October 30, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, DC 20549 RE: Diffusion Pharmaceuticals Inc. Withdrawal of Request for Acceleration of Registration Statement on Form S-1 (File No. 333-234234) Ladies and Gentlemen: Diffusion Pharmaceuticals Inc. (the “Registrant”) hereby withdraws its request, dated October 28, 2019, that the Registration Statement on Form S-1 (File No. 333-234234) (the “Registration Statement”) become effective on Wednesday, October 30, 2019, at 5:15 p.m., or as soon as practicable thereafter. The Registrant is no longer requesting that such Registration Statement be declared effective at this time and we hereby formally withdraw our request for acceleration of the effective date. If you have any questions regarding the foregoing, please contact our counsel, David Rosenthal of Dechert LLP at (212) 698-3616, or Curtis Weber of Dechert LLP at (212) 649-8705. Very truly yours, DIFFUSION PHARMACEUTICALS INC. /s/ David G. Kalergis David G. Kalergis Chief Executive Officer